Literature DB >> 15134303

Optimization of treatment in Turner's syndrome.

R Gracia Bouthelier1, A Oliver Iguacel, Isabel Gonzalez Casado, A Alcalde de Alvaré.   

Abstract

We discuss treatment for short stature and hypogonadism in patients with Turner's syndrome, using recombinant human growth hormone (GH) and estrogen. We discuss the starting dose of GH, age at start of treatment, and association with oxandrolone or low dose estrogen therapy before 12 years old. We provide recommendations for optimization of therapy for best final height and induction of puberty with estrogen therapy. Our experience in the Children's Endocrinology Clinic in "La Paz" University Hospital, Madrid, is that 83% of our patients need estrogen therapy and only 17% had spontaneous menarche. The average age for puberty induction was 12.2 years, and the average duration of estrogen treatment was 2.1 years. The average final height obtained using GH treatment was 151.3 cm with a gain related to predicted height of 6.8 cm.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15134303

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  1 in total

1.  Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome.

Authors:  Chiara Castronovo; Raffaella Rossetti; Daniela Rusconi; Maria P Recalcati; Chiara Cacciatore; Elena Beccaria; Valeria Calcaterra; Pietro Invernizzi; Daniela Larizza; Palma Finelli; Luca Persani
Journal:  Hum Reprod       Date:  2013-12-08       Impact factor: 6.918

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.